Literature DB >> 3264814

Specific inhibition of the DNA-anti-DNA immune reaction by low molecular weight anionic compounds.

E Ben-Chetrit1, D Eilat, S A Ben-Sasson.   

Abstract

The structural features of the interaction between DNA and lupus anti-DNA antibodies were investigated by competition experiments with low molecular weight synthetic compounds. It was found that two correctly spaced chemical components, a substituted aromatic ring system and a negatively charged acidic residue, were required for the binding of most anti-DNA autoantibodies to their respective antigens. These chemical elements are combined in the structure of several anionic dyes, including some certified food colours. The dyes were found to interfere efficiently and specifically with the lupus DNA-anti-DNA immune reaction. Therefore, this family of compounds may serve as a basis for the development of a new approach to drug therapy in SLE.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264814      PMCID: PMC1385490     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Treatment of lupus nephritis in adult (NZB + NZW)F1 mice by cortisone-facilitated tolerance to nucleic acid antigens.

Authors:  Y Borel; R M Lewis; J André-Schwartz; B D Stollar; E Diener
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

2.  Radioimmunoassay of antibodies to acetylcholine receptor in serum of myasthenia gravis patients.

Authors:  T Brenner; O Abramsky; R P Lisak; B Zweiman; R Tarrab-Hazdai; S Fuchs
Journal:  Isr J Med Sci       Date:  1978-09

3.  Antigen-binding diversity and idiotypic cross-reactions among hybridoma autoantibodies to DNA.

Authors:  C Andrzejewski; J Rauch; E Lafer; B D Stollar; R S Schwartz
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

4.  Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids.

Authors:  E M Lafer; J Rauch; C Andrzejewski; D Mudd; B Furie; B Furie; R S Schwartz; B D Stollar
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

5.  A ribonucleic acid-specific antibody produced during autoimmune disease: evidence for nucleotide sequence specificity.

Authors:  D Eilat; S A Ben Sasson; R Laskov
Journal:  Eur J Immunol       Date:  1980-11       Impact factor: 5.532

6.  Murine lupus anti-DNA antibodies cross-react with the hapten (4-hydroxy-5-iodo-3-nitrophenyl)acetyl, but immunization-induced anti-DNA antibodies do not.

Authors:  M Zouali; P Migliorini; D B Stollar
Journal:  Eur J Immunol       Date:  1987-04       Impact factor: 5.532

7.  Antibodies to RNA from autoimmune NZB/NZW mice recognize a similar antigenic determinant and show a large idiotypic diversity.

Authors:  D Eilat; M Hochberg; R Fischel; R Laskov
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

8.  Monoclonal autoantibodies: an approach to studying autoimmune disease.

Authors:  D Eilat
Journal:  Mol Immunol       Date:  1982-07       Impact factor: 4.407

9.  In vitro demonstration of a particular affinity of glomerular basement membrane and collagen for DNA. A possible basis for a local formation of DNA-anti-DNA complexes in systemic lupus erythematosus.

Authors:  S Izui; P H Lambert; P A Miescher
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

10.  Immunological studies concerning the nephritis of systemic lupus erythematosus.

Authors:  D Koffler; P H Schur; H G Kunkel
Journal:  J Exp Med       Date:  1967-10-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Lessons about autoantibody specificity in systemic lupus erythematosus from animal models.

Authors:  D I Stott
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

2.  Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation.

Authors:  M Shlomchik; M Mascelli; H Shan; M Z Radic; D Pisetsky; A Marshak-Rothstein; M Weigert
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.